Overview

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

Status:
Completed
Trial end date:
2017-12-30
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Acipimox